Literature DB >> 33362756

The Murine CD137/CD137 Ligand Signalosome: A Signal Platform Generating Signal Complexity.

Beom K Choi1, Hyeon-Woo Lee2.   

Abstract

CD137, a member of the TNFR family, is a costimulatory receptor, and CD137L, a member of the TNF family, is its ligand. Studies using CD137- and CD137L-deficient mice and antibodies against CD137 and CD137L have revealed the diverse and paradoxical effects of these two proteins in various cancers, autoimmunity, infections, and inflammation. Both their cellular diversity and their spatiotemporal expression patterns indicate that they mediate complex immune responses. This intricacy is further enhanced by the bidirectional signal transduction events that occur when these two proteins interact in various types of immune cells. Here, we review the biology of murine CD137/CD137L, particularly, the complexity of their proximal signaling pathways, and speculate on their roles in immune responses.
Copyright © 2020 Choi and Lee.

Entities:  

Keywords:  CD137; CD137 ligand; CD137/CD137L-mediated immune modulation; bi-directional signal transduction pathways; signalosome

Mesh:

Substances:

Year:  2020        PMID: 33362756      PMCID: PMC7758191          DOI: 10.3389/fimmu.2020.553715

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  129 in total

1.  Expression of soluble CD137 correlates with activation-induced cell death of lymphocytes.

Authors:  J Michel; H Schwarz
Journal:  Cytokine       Date:  2000-06       Impact factor: 3.861

2.  Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-gamma.

Authors:  Beom K Choi; Young H Kim; Chang H Kim; Moon S Kim; Kwang H Kim; Ho S Oh; Myoung J Lee; Don K Lee; Dass S Vinay; Byoung S Kwon
Journal:  J Immunol       Date:  2010-07-07       Impact factor: 5.422

3.  Levels of soluble CD137 are enhanced in sera of leukemia and lymphoma patients and are strongly associated with chronic lymphocytic leukemia.

Authors:  M Furtner; R H Straub; S Krüger; H Schwarz
Journal:  Leukemia       Date:  2005-05       Impact factor: 11.528

4.  Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses.

Authors:  Seung-Woo Lee; Yunji Park; Aihua Song; Hilde Cheroutre; Byoung S Kwon; Michael Croft
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

5.  Inhibition of 4-1BBL-regulated TLR response in macrophages ameliorates endotoxin-induced sepsis in mice.

Authors:  Bo Ram Bang; Sang Jick Kim; Hideo Yagita; Michael Croft; Young Jun Kang
Journal:  Eur J Immunol       Date:  2015-01-21       Impact factor: 5.532

Review 6.  Immune regulation by 4-1BB and 4-1BBL: complexities and challenges.

Authors:  Chao Wang; Gloria H Y Lin; Ann J McPherson; Tania H Watts
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

7.  Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.

Authors:  Qiao Li; Abbey Carr; Fumito Ito; Seagal Teitz-Tennenbaum; Alfred E Chang
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

8.  Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling.

Authors:  Aruna Bitra; Tzanko Doukov; Jing Wang; Gaelle Picarda; Chris A Benedict; Michael Croft; Dirk M Zajonc
Journal:  J Biol Chem       Date:  2017-12-14       Impact factor: 5.157

9.  TRAF molecules in cell signaling and in human diseases.

Authors:  Ping Xie
Journal:  J Mol Signal       Date:  2013-06-13

10.  CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand.

Authors:  K Saoulli; S Y Lee; J L Cannons; W C Yeh; A Santana; M D Goldstein; N Bangia; M A DeBenedette; T W Mak; Y Choi; T H Watts
Journal:  J Exp Med       Date:  1998-06-01       Impact factor: 14.307

View more
  4 in total

1.  Isotype-specific plasma cells express divergent transcriptional programs.

Authors:  Brett W Higgins; Andrew G Shuparski; Karen B Miller; Amanda M Robinson; Louise J McHeyzer-Williams; Michael G McHeyzer-Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-15       Impact factor: 12.779

Review 2.  Novel Discoveries in Immune Dysregulation in Inborn Errors of Immunity.

Authors:  Anwen Ren; Wei Yin; Heather Miller; Lisa S Westerberg; Fabio Candotti; Chan-Sik Park; Pamela Lee; Quan Gong; Yan Chen; Chaohong Liu
Journal:  Front Immunol       Date:  2021-08-27       Impact factor: 7.561

3.  Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer.

Authors:  David S Hong; Ajay K Gopal; Alexander N Shoushtari; Sandip P Patel; Aiwu R He; Toshihiko Doi; Suresh S Ramalingam; Amita Patnaik; Shahneen Sandhu; Ying Chen; Craig B Davis; Timothy S Fisher; Bo Huang; Kolette D Fly; Antoni Ribas
Journal:  Front Immunol       Date:  2022-08-02       Impact factor: 8.786

4.  Role of ADAM10 and ADAM17 in Regulating CD137 Function.

Authors:  Jana Seidel; Sinje Leitzke; Björn Ahrens; Maria Sperrhacke; Sucharit Bhakdi; Karina Reiss
Journal:  Int J Mol Sci       Date:  2021-03-08       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.